Affidea, Subtle Medical bring AI collaboration to Italy

Affidea, a European healthcare provider with more than 240 locations, announced it is now implementing Subtle Medical’s SubtlePET solution in its PET-CT center in Italy.

SubtlePET has already received CE certification and uses AI to speed up PET scans. The solution also makes the entire imaging process much more comfortable for patients and helps physicians see more patients in a given day.

“At Affidea, we uphold our commitment to lead healthcare transformation by adopting the most innovative technologies which can support us in improving patients’ care,” Giuseppe Recchi, Affidea’s CEO, said in a prepared statement. “With this new AI solution, Affidea IRMET becomes the first PET/CT center in Europe to pioneer this ground-breaking software for a better patient experience and increased efficiency with the same high-quality standards. We are delighted to partner with Subtle Medical as we both are at the forefront of innovation in imaging with one common goal: better care, better patient experience.”

“Our mission is to make medical imaging safer and more comfortable for patients all over the world while helping hospitals increase productivity by enabling more efficient scans,” Enhao Gong, PhD, CEO of Subtle Medical, said in the same statement. “We're looking forward to our partnership with Affidea and expanding our value beyond the U.S.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.